Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease
Status:
Completed
Trial end date:
2020-10-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of vedolizumab intravenous
(IV) infusion as induction treatment in Chinese participants withmoderately to severely
active Crohn's disease (CD) at Week 10.